Key result
Early statin therapy in acute cardioembolic stroke may reduce major vascular events and death.
Why the study?
Does starting statin therapy during the acute stage of ischemic stroke reduce the risk of major vascular events and death in patients with cardioembolic stroke with no guidance-based indication?
Does starting statin therapy during the acute stage of ischemic stroke reduce the risk of major vascular events and death in patients with cardioembolic stroke with no guidance-based indication?
Starting statin therapy in the acute stage of cardioembolic stroke may improve clinical outcomes even in patients without a guideline-based indication.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open whether statins benefit acute cardioembolic stroke without indication.
Starting statin during the acute stage of ischemic stroke may reduce the risk of major vascular events, vascular death, and all-cause death in patients with cardioembolic stroke with no guidance-based indication for statin.
No takes yet. Share an insight, caveat, or question.
Park et al. (2020) studied this question. Initiating statin therapy in acute cardioembolic stroke may reduce the risk of major vascular events and death compared to no treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: